Inhaled biologics: opportunities, challenges, and insights in drug delivery device development

Approximately 40% of all FDA drug approvals in 2022 and 2023 were biologics. It's clear that the opportunities presented by inhaled biologics are still untapped. However, developing inhaled biologics presents several challenges. In this video, TTP’s Ben Hatton, Project Lead, and Svilen Savov, Head of Respiratory, delve into the complexities, advantages and opportunities of inhaled biologics, highlighting the importance of remaining device agnostic, innovating only where necessary, and minimising risks through seamless integration of formulation and device engineering teams